FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL							
OMB Number:	3235-0104						
Estimated average burden							
hours per response:	0.5						

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Bingham James B.	2. Date of Event Requiring Stater (Month/Day/Yea 05/08/2019	nent	3. Issuer Name and Ticker or Trading Symbol NextCure, Inc. [NXTC]							
(Last) (First) (Middle) C/O NEXTCURE, INC.			Relationship of Reporting Person(s) (Check all applicable) Director 10		r (Mc	5. If Amendment, Date of Original Filed (Month/Day/Year)				
9000 VIRGINIA MANOR ROAD, SUITE 200			X Officer (give title below) Chief Development	Other (spectod) t Officer	App	Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person				
(Street) BELTSVILLE MD 20705						-	y More than One			
(City) (State) (Zip)										
Table I - Non-Derivative Securities Beneficially Owned										
1. Title of Security (Instr. 4)			2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)		t (D) (Inst	4. Nature of Indirect Beneficial Ownership (Instr. 5)				
Common Stock			87,131	D	D					
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)										
1. Title of Derivative Security (Instr. 4) 2. Date Exerc Expiration Da (Month/Day/Y					4. Conversion or Exercise	cise Form:	6. Nature of Indirect Beneficial Ownership (Instr. 5)			
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Price of Derivative Security	Direct (D) or Indirect (I) (Instr. 5)				
Employee Stock Option (Right to Buy)	(1)	03/15/2027	Common Stock	18,671	1.21	D				
Employee Stock Option (Right to Buy)	(2)	08/27/2028	Common Stock	37,342	1.77	D				
Employee Stock Option (Right to Buy)	(3)	12/21/2028	Common Stock	87,131	7.63	D				

Explanation of Responses:

- 1. One fourth of the option vested on March 15, 2018. The remainder vests in 36 monthly installments beginning on April 15, 2018.
- 2. One fourth of the option vested on March 15, 2019. The remainder vests in 36 monthly installments beginning on April 15, 2019.
- $3. \ One fourth of the option vests on December 21, 2019. \ The remainder vests in 36 monthly installments beginning on January 21, 2019.$

Remarks:

Exhibit 24 - Power of Attorney

/s/ Steven P. Cobourn, as attorney-in-fact for James B.

05/08/2019

Date

Bingham

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

NEXTCURE, INC.

SECTION 16 POWER OF ATTORNEY

Know all by these presents, that the undersigned hereby constitutes and appoints each of Michael Richman, Steven P. Coburn and Timothy Mayer, Ph.D. the undersigned's true and lawful attorney-in-fact to:

- (1) execute for and on behalf of the undersigned, in the undersigned's capacity as an officer and/or director of NextCure, Inc. (the "Company"), Forms 3, 4 and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934, as amended, and the rules thereunder;
- do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4, or 5 and timely file such form with the United States Securities and Exchange Commission and any stock exchange or similar authority; and
- (3) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934, as amended.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 2nd day of May 2019.

/s/ James B. Bingham, Ph.D. James B. Bingham, Ph.D.